GENMAB A/S/S (GMXAY) Stock Price, News & Analysis

Company Overview

Genmab A/S is a Denmark-based biotechnology company specializing in the creation and development of proprietary antibody therapeutics for the treatment of cancer and autoimmune diseases. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has focused on leveraging its innovative antibody platforms—such as DuoBody, HexaBody and DuoHexaBody—to generate next-generation therapies. The company’s expertise extends from early discovery through preclinical development, after which it partners with larger biopharmaceutical firms to advance candidates through clinical trials and commercialization.

Among Genmab’s most notable products is daratumumab, marketed under the brand name DARZALEX in collaboration with Janssen, which has become a leading monoclonal antibody for the treatment of multiple myeloma. The company also partnered with GlaxoSmithKline on ofatumumab (Kesimpta) for relapsing multiple sclerosis and with Roche on epcoritamab for certain B-cell malignancies. These partnerships illustrate Genmab’s business model of co-development and out-licensing, enabling global reach while retaining exposure to late-stage clinical and commercial milestones.

Genmab’s leadership team is headed by Chief Executive Officer Jan van de Winkel, Ph.D., whose tenure has overseen the expansion of the company’s pipeline and its entry into combination therapies. Research and manufacturing operations are based in Copenhagen and Utrecht, with additional research offices in smart biotech hubs to support both European and North American clinical programs. Through ongoing collaborations and in-house discovery efforts, Genmab continues to advance a diversified pipeline aimed at solid tumors, hematologic cancers and selected immunological disorders.

Key Stats

• Today's Range: $32.51 to $32.93
• 50-Day Range: $21.43 to $33.56
• 52-Week Range: $12.10 to $19.00
• Volume: 1.57 million shs
• Average Volume: 48,553 shs
• Market Capitalization: N/A
• P/E Ratio: 12.57
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GMXAY Stock Analysis - Frequently Asked Questions

How have GMXAY shares performed this year?

GENMAB A/S/S's stock was trading at $20.77 at the beginning of 2025. Since then, GMXAY stock has increased by 57.6% and is now trading at $32.74.

How do I buy shares of GENMAB A/S/S?

Shares of GMXAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:GMXAY
• CIK: N/A
• Web: www.genmab.com
• Phone: 45 70 20 27 28
• Fax: N/A
• Employees: 1,660
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 12.57
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A